Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
Sponsored by Emory University
About this study
To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
To determine the optimal schedule for three-dimensional verification imaging and necessary re-planning of patients undergoing IMPT for a rapidly changing tumor (small cell lung cancer). * To determine the rate of cardiac toxicities from IMPT in patients with small cell lung cancer compared with historical controls receiving photon-based treatment. * To determine the rate of pneumonitis and esophagitis from IMPT and compare with historical controls receiving photon based treatment.
Where this study is enrolling
- I'm interested
Winship Cancer Institute
Atlanta, Georgia
Who can participate
Inclusion criteria
- ✓Pathologically confirmed small cell lung cancer, limited or extensive stage.
- ✓Patients who are offered thoracic radiotherapy with intensity-modulated proton therapy (IMPT) techniques delivering 30-66 Gy in 15-33 fractions at 2 Gy per fraction, at the recommendation of the treating radiation oncologist.
- ✓Age 18 or greater
Exclusion criteria
- ✕Prior radiation therapy which would provide significant dose overlap with the planned target volume(s)
- ✕Pregnancy
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.